| RNWAX | TEMVX | RNWAX / TEMVX | |
| Total Expense Ratio | 1.66 | 0.00 | - |
| Annual Report Gross Expense Ratio | 1.66 | 0.89 | 187% |
| Fund Existence | 24 years | 8 years | - |
| Gain YTD | 13.903 | 20.430 | 68% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 90.9B | 1.96B | 4,647% |
| Annual Yield % from dividends | 0.49 | 3.57 | 14% |
| Returns for 1 year | 20.59 | 43.86 | 47% |
| Returns for 3 years | 46.08 | 73.05 | 63% |
| Returns for 5 years | 9.71 | 0.83 | 1,169% |
| Returns for 10 years | 112.99 | N/A | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FBDIX | 189.03 | N/A | N/A |
| Franklin Biotechnology Discovery A | |||
| POMIX | 77.59 | N/A | N/A |
| T. Rowe Price Total Equity Market Idx | |||
| TPYYX | 8.52 | N/A | N/A |
| Touchstone Sands Capital Intl Gr Eq Y | |||
| VWNDX | 23.48 | N/A | N/A |
| Vanguard Windsor Investor Shares | |||
| FACSX | 57.32 | N/A | N/A |
| Nuveen Mid Cap Value Opportunities C | |||